#68
Meaningful Relevance
Clinically useful for understanding dosing variability and formulation effects, but still too heterogeneous to function as a definitive prescribing guide.
Pharmacokinetics
THC
CBD
Drug Formulation
| Audience | Clinicians, patients, caregivers, formulators, and readers trying to make better sense of cannabis dosing science |
| Primary Topic | How THC and CBD pharmacokinetics change with route, formulation, food, metabolism, and patient-specific factors |
| Source | Read the full article |
Cannabis Pharmacokinetics Review, of THC and CBD, What This Review Clarifies, and Why Dosing Still Requires Caution
This is a broad evidence review of human pharmacokinetic studies, not a single controlled trial, and its value lies in showing why cannabinoid exposure can shift substantially with route, formulation, food, metabolism, and patient context. That makes it useful, but not yet precise enough to function as a universal prescribing roadmap.
This is an evidence review of human pharmacokinetic studies on THC and CBD. Its core contribution is showing that route of administration, formulation, meal timing, co-administered drugs, sex, and organ function can all meaningfully alter cannabinoid exposure. Its biggest limitation is that it synthesizes highly heterogeneous studies rather than producing one clinically validated dosing framework.
Cannabis medicine often sounds simpler than it is. Readers may hear one dose, one product, or one cannabinoid discussed as though its effects are stable across people and situations, yet this review makes clear that absorption and exposure can change sharply depending on whether cannabinoids are inhaled, swallowed, taken with fat, delivered in an oil or nanoformulation, or used in a patient with altered metabolism. That matters directly to counseling, symptom timing, adverse-effect risk, and why guides such as cannabis dosage and application guidance need to be treated as individualized starting points rather than rigid formulas.
| Study Type | Evidence review of human pharmacokinetic studies |
| Population | Healthy volunteers and patient populations, including people with epilepsy, chronic pain, anxiety, multiple sclerosis, Alzheimer disease, renal impairment, and hepatic impairment |
| Exposure or Intervention | THC and CBD delivered through oral, inhaled, vaporized, oromucosal, sublingual, topical, and transdermal formulations |
| Comparator | No single formal comparator across the whole paper; the review compares routes, formulations, meals, and patient factors across included studies |
| Primary Outcomes | Pharmacokinetic measures such as Cmax, Tmax, AUC, half-life, metabolism, and formulation-dependent bioavailability |
| Sample Size or Scope | PubMed and Scopus search from 2020 to 2025; 279 records screened, 140 assessed for eligibility, 37 original human studies included |
| Journal | Biomedicine & Pharmacotherapy |
| Year | 2025 |
| DOI | 10.1016/j.biopha.2025.118673 |
| Funding or Conflicts | No dedicated funding or conflict statement was clearly presented in the visible paper sections provided here |
This review supports a cautious, individualized approach to cannabis dosing. It helps explain why inhaled products tend to act faster, why oral products are slower and more meal-sensitive, and why patient-specific factors can meaningfully change exposure, but it does not validate one simple dose rule that fits everyone.
The authors set out to review human pharmacokinetic evidence on the two major plant cannabinoids, THC and CBD, with a particular focus on how route of administration, formulation, and patient factors shape real-world exposure. They searched PubMed and Scopus for work published from 2020 through 2025, screened 279 records, reviewed 140 full texts, and ultimately included 37 original human studies. Those studies covered healthy volunteers as well as patients with a range of conditions, and examined oral, inhaled, vaporized, oromucosal, sublingual, topical, and transdermal products. The main outcomes were pharmacokinetic parameters such as Cmax, Tmax, AUC, half-life, and metabolic handling, not one single shared clinical endpoint.
Across the compiled studies, route and formulation mattered a great deal. Inhalation generally produced faster systemic absorption and higher peak exposure than oral use, while oral products were slower, more delayed, and more vulnerable to the first-pass effect. Oil-based, water-soluble, nanoformulated, and other enhanced-delivery preparations often shifted exposure upward compared with simpler powders or conventional capsules. Food also mattered. High-fat meals tended to increase oral cannabinoid exposure, especially for CBD, and in some THC preparations fat also raised normalized peak concentrations. The review also highlights clinically relevant variability tied to sex, age, prior cannabis exposure, co-administered medications, hepatic function, and genetics. Several examples are worth noting: very high CBD doses sometimes increased THC-related adverse effects rather than softening them, likely through higher 11-OH-THC exposure; transdermal delivery produced low blood concentrations but demonstrated proof of systemic entry in at least some settings; and moderate to severe hepatic impairment appeared to justify lower starting doses and slower CBD titration.
This is helpful review-level evidence, but it is not the same thing as one unified clinical trial or a tight meta-analysis. The paper is strongest when it synthesizes broad pharmacokinetic themes, such as inhaled cannabinoids tending to peak faster than oral ones, or food and formulation shifting exposure. It is weaker when readers try to convert those broad patterns into precise treatment rules, because the underlying studies vary widely in product composition, dose, populations, sample size, endpoints, and study design. In other words, this review can sharpen judgment, but it cannot eliminate uncertainty.
The biggest issue is heterogeneity. This review is asking readers to learn from many different studies that do not line up neatly in dose, formulation, route, meal status, patient population, or clinical context. Some findings come from small exploratory studies, some from healthy volunteers, and some from narrow disease populations, which makes transportability imperfect. A second problem is that pharmacokinetic clarity is not the same as clinical outcome clarity. Knowing that one formulation reaches a higher Cmax or shorter Tmax does not automatically tell us which option is best, safest, or most durable for a particular symptom profile. A third caution is that some reassuring or intuitive narratives do not hold cleanly across the studies. For example, CBD did not uniformly buffer THC-related effects, and in very high co-administered amounts it sometimes amplified them. That makes the review educational, but also a reminder that cannabinoid simplifications can fail quickly.
This paper does not prove that one route of administration is universally best, that CBD consistently neutralizes THC side effects, or that pharmacokinetic optimization alone solves the clinical challenge of cannabis care. It does not provide one settled dosing algorithm for anxiety, pain, epilepsy, sleep, or spasticity. It also does not mean that faster absorption is always preferable, or that higher exposure is inherently more therapeutic. Readers who want certainty on product choice, dose timing, or long-term safety will still find important gaps.
This is a useful paper for people who want a smarter foundation for cannabis medicine. It makes clear that cannabinoid dosing is not just about milligrams. It is also about route, formulation, metabolism, meal timing, and who the patient is. That is a meaningful contribution. Still, the evidence remains too mixed to treat this review as a finalized prescribing playbook. The most responsible takeaway is not certainty, but better calibration.
? Join the Conversation
Questions about timing, dosing, or product type often start here. Ask Dr. Caplan.
This section stays brief on purpose. One review can improve clarity, but it cannot substitute for individualized medical judgment.
Share this review with a colleague, patient, or caregiver who wants a more realistic understanding of why cannabis dosing can be so variable.
Primary source: Kaszewska M, Woźniczka K, Sztormowska-Achranowicz K, et al. Perspectives of cannabis-based medicines in a view of pharmacokinetic studies of Δ9-THC and CBD in humans. Biomedicine & Pharmacotherapy. 2025;192:118673. Read the paper
1. Is this paper about whether cannabis works for disease?
Not primarily. It is mostly about how THC and CBD move through the body, and how that changes with route, formulation, meals, and patient factors.
2. What is the biggest practical lesson for patients?
The same cannabinoid can behave very differently depending on how it is taken. Timing, intensity, and duration are not fixed properties of the label alone.
3. Did the review suggest inhalation is best?
No. It suggested inhalation is faster and often reaches higher peaks, but that does not make it universally best. Speed, predictability, adverse effects, and dosing control all matter.
4. Why does food matter so much?
Cannabinoids are lipophilic, so meal composition, especially fat content, can change absorption and exposure. That can alter how strongly or how long a product feels.
5. Does CBD always reduce THC side effects?
No. This review includes studies in which very high CBD co-dosing increased THC-related unpleasant effects, likely through metabolic interactions.
6. Are topicals and transdermals the same thing?
Not exactly. Topicals are often intended for more local effects, while transdermal systems aim to move cannabinoids into systemic circulation. This review suggests bloodstream exposure from skin delivery is usually low, though not always absent.
7. Does this paper give a precise dosing schedule for clinicians?
No. It supports individualized titration and better dose reasoning, but it does not replace disease-specific clinical judgment or regulatory labeling.
8. What does it say about liver impairment?
The review points to lower starting doses and slower titration for CBD in moderate to severe hepatic impairment, because metabolism and exposure can shift meaningfully.
9. Is this review more useful for clinicians or lay readers?
Both, if read carefully. Clinicians can use it to refine PK thinking, and lay readers can use it to understand why cannabis responses can feel unpredictable.
10. What is the fairest overall conclusion?
This review meaningfully improves our understanding of THC and CBD dosing variability, but it still leaves important gaps around standardization, clinical translation, and long-term safety.
